Effects of long-term in vivo treatment of mice with purified murine recombinant GM-CSF.
Normal adult BDF1 mice were injected s.c. with 1 or 10 micrograms/kg/day of recombinant murine granulocyte-macrophage colony-stimulating factor (rmGM-CSF; specific activity 3.9 x 10(7) U/mg) for periods up to 11 weeks. After 1, 3, 7, 9, or 11 weeks, groups of three mice were killed and various hematological parameters were evaluated. Such treatment induced a sustained increase in the number and phagocytic activity of peritoneal macrophages, increased weight and cellularity of the spleen, and increased numbers of lineage-restricted precursor cells and multipotent stem cells in the spleen. No significant differences in blood cell numbers or differential counts were observed during the experiment. Femoral granulocyte-macrophage colony-forming cells (GM-CFCs), mixed-lineage colony-forming cells (Mix-CFCs), and 7- and 12-day spleen colony-forming units (CFU-S) were increased in the first week of treatment, but returned to normal (or subnormal levels) later. Examination of histological preparations of liver, lung, skin, ileum, thymus, Peyer's patches, kidney, skin, and brain revealed no differences from control preparations. Mast cell numbers were not increased in any of these tissues. Despite continuing treatment, most hematological parameters normalized upon prolonged rmGM-CSF treatment. The reasons for this are unclear but are not apparently due to the presence of inhibitory factors in the blood of treated mice. The results indicate little evidence of side effects during prolonged therapy with doses of rGM-CSF commonly used in clinical situations.
Pojda
Z
Z
Department of Experimental Hematology, Paterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute, Manchester, England.
Molineux
G
G
Dexter
T M
TM
D000818:Animals; D001854:Bone Marrow Cells; D003115:Colony-Stimulating Factors / Q000008:administration & dosage* / Q000009:adverse effects; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006133:Growth Substances / Q000008:administration & dosage* / Q000009:adverse effects; D006400:Hematocrit; D006410:Hematopoiesis / Q000187:drug effects*; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D008264:Macrophages / Q000502:physiology; D051379:Mice; D009929:Organ Size; D010587:Phagocytosis / Q000187:drug effects; D011994:Recombinant Proteins; D013154:Spleen / Q000166:cytology; D013997:Time Factors
D003115:Colony-Stimulating Factors; D006133:Growth Substances; D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor